CMND (Clearmind Medicine) Buyback Yield % : -10.30 (As of Dec. 15, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Clearmind Medicine Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Clearmind Medicine's current buyback yield was -10.30%.

Clearmind Medicine Buyback Yield % Historical Data

The historical data trend for Clearmind Medicine's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clearmind Medicine Buyback Yield % Chart

Clearmind Medicine Annual Data

Trend

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Buyback Yield %

Get a 7-Day Free Trial

-19.55

-4.11

-361.86

Clearmind Medicine Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
Buyback Yield %	Get a 7-Day Free Trial															2.81	227.46	-161.06	-	-6.24

Competitive Comparison of Clearmind Medicine's Buyback Yield %

For the Biotechnology subindustry, Clearmind Medicine's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clearmind Medicine's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearmind Medicine's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Clearmind Medicine's Buyback Yield % falls into.

Clearmind Medicine Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Clearmind Medicine's Buyback Yield for the fiscal year that ended in Oct. 2023 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	8.037)	/	2.22104238
	=	-361.86%

Clearmind Medicine's annualized Buyback Yield for the quarter that ended in Jul. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock		(Annualized)			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	*	Annualized Factor	/	Market Cap
	=	- (0	+	0.103)	*	4	/	6.6055384
	=	-6.24%

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Jul. 2024) data.

Clearmind Medicine Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Clearmind Medicine's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Clearmind Medicine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearmind Medicine Inc (NAS:CMND) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

CWY0:Germany

Address

101-1220 West 6th Avenue, Vancouver, BC, CAN, V6H 1A5

Website

https://www.clearmindmedicine.com

Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.